[Intravenous polyclonal immunoglobulins (IVIG): what use in transplantation?].
Intravenous human polyclonal immunoglobulins G (IVIg) were initially used as substitutive therapy for primary and secondary immunodeficiencies then for various autoimmune diseases. More recently they were proposed in organ transplant recipients as they induce a decrease of the anti-HLA antibodies titer in HLA immunized patients. Few retrospective and prospective trials have been performed yet, though they clearly show a beneficial effect of IVIg on kidney graft survival. This paper reviews the different potential mechanisms of action of IVIg their use and potential efficacy in organ transplant recipients.
Haymann
J P
JP
Service de néphrologie A, INSERM U 489, Hôpital Tenon, Paris.
Glotz
D
D
D000888:Antibodies, Anti-Idiotypic; D006084:Graft Rejection / Q000628:therapy; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D014181:Transplantation Immunology
D000888:Antibodies, Anti-Idiotypic; D006680:HLA Antigens; D016756:Immunoglobulins, Intravenous
Immunoglobulines polyclonales intraveineuses (IVIg): quel intérêt en transplantation?